Table 1.
Demographic characteristics and prevalent vs newly detected carcinogenic human papillomavirus (HPV) infections among women in the Guanacaste cohort by screening group*
| Carcinogenic HPV infections |
|||||||
| Screening group | No. of women | Mean age at enrollment, y | Median annual-time-bins, y | Baseline prevalence† (95% CI) | Cumulative new detection‡ (95% CI) | No. present at baseline§ | No. detected during follow-up§ |
| Total cohort | 10 049 | 41.0 | 6 | 1183/9153 = 12.9% (12.2% to 13.6%) | 1020/7811 =13.1% (12.3% to 13.8%) | 1468 | 1420 |
| Censored at enrollment | 955 | 50.4 | n/a | 257/915 = 28.1% (25.2% to 31.1%) | n/a | 340 | n/a |
| Actively followed | 3065 | 37.0 | 7 | 615/2625 = 23.4% (21.8% to 25.1%) | 673/2844 = 23.7% (22.1% to 25.3%) | 765 | 981 |
| Not sexually active at enrollment | 410 | 21.0 | 7 | n/a | 90/256 = 35.2% (29.3% to 41.3%) | n/a | 138 |
| Screen positive | 2115 | 38.4 | 7 | 584/2099 = 27.8% (25.9% to 29.8%) | 510/2069 = 24.7% (22.8% to 26.6%) | 734 | 749 |
| Screen negative║ | 540 | 43.9 | 7 | 31/526 = 5.9% (4.0% to 8.3%) | 73/519 = 14.1% (11.2% to 17.4%) | 31 | 94 |
| Passively followed¶ | 6029 | 41.6 | 6 | 311/5613 = 5.5% (5.0% to 6.2%) | 347/4967 = 7.0% (6.3% to 7.7%) | 363 | 439 |
CI = confidence interval; n/a = not applicable; time-bin = 1-y interval where HPV test results were consolidated as one result for each type-specific infection. The following HPV types were considered as carcinogenic: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68.
Proportion of women with at least one carcinogenic HPV infection at enrollment among sexually active women who were screened and had adequate test results.
Proportion of women with new type-specific HPV infections among women who were ever in follow-up, who were sexually active or became sexually active during follow-up, and who were HPV negative at enrollment for that HPV type.
Women can contribute one or more type-specific carcinogenic HPV infections at either enrollment and/or follow-up.
Random sample of women who had negative enrollment test results and would have been part of the passive cohort if not selected as a random sample for active follow-up.
Women who at enrollment had negative cytology and cervigram results, normal looking cervices by naked eye inspection, tested negative for HPV DNA by hybrid capture tube test (see “Methods”), and who were screened at enrollment and on average 5.4 y after enrollment.